Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Operating Leases (2019 - 2025)

Avidity Biosciences' Operating Leases history spans 7 years, with the latest figure at $49.3 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 1565.57% year-over-year to $49.3 million; the TTM value through Dec 2025 reached $49.3 million, up 1565.57%, while the annual FY2025 figure was $49.3 million, 1565.57% up from the prior year.
  • Operating Leases reached $49.3 million in Q4 2025 per RNA's latest filing, down from $50.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $50.0 million in Q3 2025 to a low of $877000.0 in Q3 2021.
  • Average Operating Leases over 5 years is $9.6 million, with a median of $6.3 million recorded in 2023.
  • The largest YoY upside for Operating Leases was 1565.57% in 2025 against a maximum downside of 73.79% in 2025.
  • A 5-year view of Operating Leases shows it stood at $10.0 million in 2021, then dropped by 23.88% to $7.6 million in 2022, then decreased by 18.06% to $6.2 million in 2023, then plummeted by 52.41% to $3.0 million in 2024, then soared by 1565.57% to $49.3 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Operating Leases are $49.3 million (Q4 2025), $50.0 million (Q3 2025), and $1.2 million (Q2 2025).